



NATCAN Outlier Policy

Version	1.2
Document Author(s)	Clare Peckitt, Marina Parry, Sarah Cook, David Cromwell, Karen Darley, Angela Kuryba, Emily Mayne, Augusto Nembrini da Rocha, Julie Nossiter, Kate Walker
Document Reviewer(s)	NATCAN Board
Effective Date	11.06.2025
Review Date	Annually

Version	Date	Author	Description of Changes	Approved By
1.0	09.05.2025	Clare Peckitt	Initial draft created.	
1.1	06.06.2025	Marina Parry	Amended following NATCAN team review.	
1.2	16.06.2025	Marina Parry	Amended following NATCAN Board	Julie on behalf of NATCAN Board following meeting on 11 th June 2025

Contents

Pur	······································	2
Sco		2
Def	ons	3
Pro	ıre	4
1	Choosing appropriate Performance Indicator(s) to be used in the outlier process	4
2	Detecting a potential negative outlier provider	4
3	Managing a potential negative 'alarm' outlier provider	5
Т	1: Steps to manage a potential 'alarm' outlier provider	6
4	Managing a potential negative 'alert' outlier	. 10
5	Managing a potential positive outlier	. 10
6	Actions when data issues are identified during the 'alarm' outlier management process	. 10
Ref	ces	. 10
Арр	ix 1: Audit Specific Outlier Policy Details	. 11
T	A1.1: Details of the National Kidney Cancer Audit outlier process	12
Т	A1.2: Details of the National Kidney Cancer Audit performance indicators used in outlier process	12
T	A2.1: Details of the National Pancreatic Cancer Audit outlier process	13
T	A2.2: Details of the National Pancreatic Cancer Audit performance indicators used in outlier proces	s13
Т	A3.1: Details of the National Non-Hodgkin Lymphoma Audit outlier process	. 14
T	A3.2: Details of the NNHLA performance indicators used in outlier process	. 14
T	A4.1: Details of the National Ovarian Cancer Audit outlier process	. 15
T	A4.2: Details of the National Ovarian Cancer Audit performance indicators used in outlier process	. 15
Т	A5.1: Details of the National Primary Breast Cancer Audit outlier process	. 16
T	A5.2: Details of the National Primary Cancer Audit performance indicators used in outlier process	. 16
Т	A6.1: Details of the National Bowel Cancer Audit outlier process	17
T	A6.2: Details of the National Bowel Cancer Audit performance indicators used in outlier process	. 17
T	A7.1: Details of the National Oesophago-Gastric Cancer Audit outlier process	. 21
	A7.2: Details of the National Oesophago-Gastric Cancer Audit performance indicators used in outliess	
T	A8.1: Details of the National Prostate Cancer Audit outlier process	. 22
T	A8.2: Details of the National Prostate Cancer Audit performance indicators used in outlier process .	23

Purpose

This Outlier Policy for the National Cancer Audit Collaborating Centre (NATCAN) describes the process used by the national cancer audits for managing providers with indicator values that fall outside the expected range of performance (i.e, are flagged as an outlier).

It is designed to provide transparency about how indicators covered by the Outlier Policy will be presented, and describe how the audits will communicate with providers so that they can investigate and respond appropriately if flagged as an outlier (either with negative or positive performance). The main policy is relevant to all NATCAN audits and Appendix 1 is audit specific.

The principles used by NATCAN outlier policy are based on established practices and are consistent with HQIPs 'NCAPOP Outlier Guidance: Identification and management of outliers' in England and Wales.

The NATCAN Outlier Policy will be reviewed annually by the NATCAN Board.

Scope

The audits publish performance indicators of the quality of care received by people in England and Wales as part of the annual State of the Nation Reports. If the performance of a provider is found to fall outside the expected range for selected performance indicators during the analysis for the State of the Nation report, it is flagged as a potential outlier.

In rare circumstances, information might be provided to the audit outside the State of the Nation cycle which could suggest the presence of serious issues with clinical practice or a systems failure and that presents a risk of harm to patients. If this occurs, the audit will implement the escalation process described in Table 3 in the "Cause for Concern" guidance published by HQIP on February 2019: https://www.hqip.org.uk/wp-content/uploads/2019/02/NCAPOP-Cause-for-Concern-Guidance-Final-E-and-W-Feb-2019.pdf

Definitions

Glossary

SOP: Standard Operating Procedure, document outlining steps to complete a task.

NATCAN: National Cancer Audit Collaborative Centre
HQIP: Healthcare Quality Improvement Partnership

Performance indicators

Indicators measure one aspect of how a provider performs, which will often be a process of care or outcome that is an important marker of quality. The indicators used by the audits are selected for being valid and reliable, and for having the ability to support NHS quality assurance / quality improvement activities.

Targets / expect levels of performance

The expected performance on an indicator may be defined in several ways. In some circumstances, it will be based on external sources such as an agreed standard. In other situations, the target will be defined in relation to the typical pattern of care achieved by providers, such as the average performance for England and Wales.

Risk adjustment

On some indicators, the indicator value of a provider will be influenced by the characteristics of the patients treated there. In these circumstances, an audit will take account of these differences in case-mix by risk adjusting the indicator values. This will ensure the evaluation of performance across providers is fair. For example, patient and tumour characteristics often taken into account during a risk adjustment process include: age, sex, disease severity, patient functional status and comorbidity.

Procedure

This section summarises the steps that the audit team will follow to detect and manage potential outlier providers.

1. Choosing appropriate Performance Indicator(s) to be used in the outlier process

- Appropriate Performance Indicator(s) (PIs) should be chosen for outlier assessment by audit teams and relevant stakeholders
- PI(s) chosen must
 - o provide a valid measure of a provider's quality of care
 - be based on events that occur frequently enough to provide sufficient statistical power
- If data quality prevents any meaningful outlier analysis from being undertaken, then the provider could be considered as an alarm outlier to facilitate improvement
- In the rare circumstances in which information provided to the audit could reasonably suggest the presence of very serious issues with clinical practice or system failure that presents a risk of harm to patients, the audit will implement the cause for concern escalation process described in Table 3 in the following guidance published February 2019:
 https://www.hqip.org.uk/wp-content/uploads/2019/02/NCAPOP-Cause-for-Concern-Guidance-Final-E-and-W-Feb-2019.pdf

2. Detecting a potential negative outlier provider

- Potential negative outlier providers are most commonly detected using a control chart such as a funnel plot.
- Cancer audits typically assess the performance of many providers over a period of time using a funnel plot. In these plots, each dot represents an NHS organisation, and a solid horizontal line represents the expected level (such as the average for England and Wales). The vertical axis indicates the indicator value, while the horizontal axis shows provider activity, with dots further to the right showing the providers that care for more patients.
- Random variation will always affect indicator values, and its influence is greater among small samples. This is shown by the funnel-shaped lines, known as control limits. These lines define the region within which we would expect the indicator values to fall if the performance of providers differed from the national average (target) because of random variation.
- The control limits in a funnel plot used by the cancer audits define differences from the national average performance corresponding to where we would expect 95% (within two standard deviations [SDs]) and 99.8% (within three SDs) of providers to lie.

- An 'alarm' outlier is a provider with a performance indicator value more than three SDs in a negative direction from the national average.
- An 'alert' outlier is a provider with a performance indicator value more than two SDs (but less than 3 SDs) in a negative direction from the national average for two consecutive years.
 The condition that an estimate should be within the defined range twice in a row before it is considered an 'alert' outlier was added to reduce the chance that a provider is erroneously identified as a potential outlier.

3. Managing a potential negative 'alarm' outlier provider

If a provider is flagged as an alarm outlier, it does not necessarily indicate a problem with the quality of care given to patients. It is a statistical result and, therefore, triggers further analysis and investigation with the provider. The following Table 1 summarises the steps taken in managing a potential 'alarm' outlier provider, including the actions required, the people responsible, and the time scales.

The national cancer audits do not require providers to submit patient data directly to NATCAN. The audits use national cancer datasets supplied by the National Disease Registration Service (NHS England) and the Welsh Cancer Network. HQIPs 'NCAPOP Outlier Guidance: Identification and management of outliers' does not consider the situation where clinical audits do not collect data directly from providers. The process of data review by providers described in this policy is therefore specific to the cancer audits.

Table 1: Steps to manage a potential 'alarm' outlier provider

Step	Action required	Owner	Within working days from prior step
1	Provider with a possible performance indicator at alarm level require	Audit team	10
	scrutiny of the data handling and analyses performed to determine		(maximum
	whether:		from
			submitting
	'Alarm' status confirmed:		draft 0 of
	Potential 'alarm' status:		State of the
	proceed to step 2		Nation
			[SotN]
			report)
2	Provider lead clinician informed about potential 'alarm' status and	Audit Clinical	5
	asked to identify possible data errors or justifiable explanation(s).	leads and	
		Audit Team	
	All relevant data and analyses to be made available to the lead clinician,		
	while sending the minimum required.		
	NOTE: All patient level data should be sent encrypted and securely to the provider lead clinician and, if returned to the audit team, remain		
	encrypted.		
3	Provider lead clinician to provide written response to audit team.	Provider Lead	25
		Clinician	

Step	Action required	Owner	Within working days from prior step
4	Review of provider lead clinician's response to determine: 'Alarm' status not confirmed: It is confirmed that the data about the provider contained inaccuracies. Re-analysis of data based on information from provider no longer indicates 'alarm' status Results for provider not included in audit reports and data tables / dashboards. The publication should include the rationale, stating that the provider is no longer a potential outlier. The provider should be asked to provide a formal response which will be published by the audit team. Process closed	Audit clinical lead	20
	 'Alarm' status confirmed: Although it is confirmed that the originally supplied data were inaccurate, analysis still indicates 'alarm' status, or It is confirmed that the originally supplied data were accurate, thus confirming the initial designation of 'alarm' status The publication should include the results for the provider, stating that the provider is an outlier. The provider should be asked to provider a formal response which will be published by the audit team. proceed to step 5 		

5 Conta writte provi analy	Action required Contact provider lead clinician, preferably by phone, prior to sending written notification of confirmed 'alarm' to provider CEO and copied to provider lead clinician, medical director. All relevant data and statistical analyses, including previous response from the provider lead clinician can be made available to provider medical director and CEO.		Within working days from prior step
For E	 The outlier confirmation letter should also include the details in Step 7 below, and a request that the Trust engage with their CQC team. Relevant audit outlier policy should be provided to provider colleagues. Notify the following of confirmed 'alarm' status: CQC (clinicalaudits@cqc.org.uk), using the outlier template, and include the audit outlier policy, NHSE (england.clinical-audit@nhs.net) and NHS England Cancer Programme, Lucy Danks (l.danks@nhs.net) HQIP associate director and project manager (www.hqip.org.uk/about-us/ourteam/), HQIP NCAPOP Director of Operations, Jill Stoddart (jill.stoddart@hqip.org.uk). Vales: Notify the following of confirmed 'alarm' status: wgclinicalaudit@gov.wales HQIP associate director and project manager (www.hqip.org.uk/about-us/our-team/) 		

Step	Action required	Owner	Within working days from prior step
6	 The audit team will proceed to public disclosure of comparative information that identifies providers as alarm level outliers (in State of the Nation Reports). Providers identified as alarm level outliers will be asked for a formal response which will be published by the audit team as an addendum or footnote. Publication of audit reports will not be delayed whilst waiting for such investigation to be completed. This can be added, online, when and if it subsequently becomes available. Conversely, if there has been no response from the provider concerning their alarm outlier status, that will be published by the audit team. 	Audit team	SotN report publication date or as soon as possible after
	Providers have the Right to Reply. Three elements to consider including: 1. Confirm data and results are correct 2. Reasons for the results 3. What has been done		
7	 The CQC advise that during their routine local engagement with the providers, their inspectors will: Encourage Trusts to identify any learning from their performance and provide the CQC with assurance that the Trust has used the learning to drive quality improvement Ask the Trust how they are monitoring or plan to monitor their performance Monitor progress against any action plan if one is provided by the trust 	England = CQC	Determined by the CQC
	If an investigation has been conducted in the Trust into an alarm outlier status, it is required that the CQC and audit provider would be provided with the outcome and actions proposed. Audits may wish to engage with CQC during the process.	Trust medical director	
	This will be published by the audit provider alongside the annual results. Further, if there were no response, the audit provider would publish this on record as an absence of response.	Audit team	

4. Managing a potential negative 'alert' outlier

Following the identification of a potential 'alert' outlier the provider will be notified (as per step 2 in the alarm outlier process above) and a formal response will be required from the provider (as per step 3).

5. Managing a potential positive outlier

- A positive outlier is a provider with an estimate of a performance indicator more than three SDs in positive direction from the national average.
- Identification of positive outliers should be used to celebrate clinical excellence.
- Positive outliers should be contacted in writing and informed of their results.
- The clinical team will be encouraged to share learnings regarding their processes of care and provide opportunities for other centres to engage with the local team to see what elements of their pathway are transferrable.
- NHS England Cancer Programme, Lucy Danks (<u>l.danks@nhs.net</u>), to be informed of the positive outlier provider for each chosen performance indicator by the audit teams.

6. Actions when data issues are identified during the 'alarm' outlier management process

A provider flagged as an 'alarm' outlier on an indicator might provide evidence of data errors affecting their indicator value. They may have raised concerns about the number of patients included in the analysis or the data on the process of care / outcomes being measured, and provided evidence by provided aggregate statistics or by returning the patient-level dataset sent to them by the audit with additional data.

If a potential 'alarm' outlier is judged by the audit team to be due to a data quality issue, the audit will not publish their results in the report, data tables / dashboards, or include them in control charts (funnel plots). The audit will publish a rationale for why the result was not published and that the audit is working with the trust to improve data quality. The value will not be included in organisational level statistics, such as the range of indicator values. Summary statistics for the overall cohort such as the national average will not be updated. This will be reviewed in future iterations of the policy.

References

<u>HQIP-NCAPOP-Outlier-Guidance</u> <u>21022024.pdf</u> NCAPOP-Cause-for-Concern-Guidance-Final-E-and-W-Feb-2019.pdf

Appendix 1: Audit Specific Outlier Policy Details

Audit	All NATCAN audits running an outlier process
Version	1
Document Author(s)	NATCAN Team members
Document Reviewer(s)	NATCAN Executive Committee
Effective Date	13.06.25
Review Date	Annually

Revision History

Version	Date	Author	Description of Changes	Approved By
1.0	13.06.25	NATCAN Team members	Initial draft created.	

This Appendix is to document the audit specific details of the outlier process.

1. National Kidney Cancer Audit

Table A1.1: Details of the National Kidney Cancer Audit outlier process

Audit Name	National Kidney Cancer Audit (NKCA)
Patient cohort	National Kidney Cancer Audit (NKCA) State of the Nation Report 2025
	Patients diagnosed from 1 January 2018 and 31 December 2022 in England and 1 January 2022 and 31 December 2023 in Wales
Outliers publication	With State of the Nation report 11.09.2025
Outlier process	Alarms and positive outliers
Process to determine if repeat alerts should be rated as alarm outlier.	NA
Minor deviations from SOP	NA

Table A1.2: Details of the National Kidney Cancer Audit performance indicators used in outlier process

Indicator	Description	Risk Adjustment (Y/N)	Missingness Concern	Rationale for use
Percentage of people with metastatic RCC receiving initial SACT within 12 months of diagnosis	Proportion of people with metastatic RCC who receive initial systemic anti-cancer therapy within 12 months of diagnosis	Yes - age, gender, ethnicity, comorbidity (Charlson score) and deprivation (IMD quintile).	Patients with missing values for risk adjustment variables were allocated to a missing category for the respective variables.	Measure of care received
Percentage of people with kidney cancer who die within 30 days of SACT treatment	Proportion of people with kidney cancer who die within 30 days of receipt of systemic anticancer therapy treatment	Yes - age, gender, ethnicity, comorbidity (Charlson score) and deprivation (IMD quintile).	Patients with missing values for risk adjustment variables were allocated to a missing category for the respective variables.	Measure of care received

2. National Pancreatic Cancer Audit

Table A2.1: Details of the National Pancreatic Cancer Audit outlier process

Audit Name	National Pancreatic Cancer Audit (NPaCA)	
Patient cohort	National Pancreatic Cancer Audit (NPaCA) State of the Nation Report 2025	
	Patients diagnosed with pancreatic cancer from 1 January 2021 to 31 December 2022 in England and 1 January 2023 to 31 December 2023 in Wales	
Outliers publication	With State of the Nation report 11.09.2025	
Outlier process	Alarm	
Process to determine if repeat alerts should be rated as alarm outlier	Classified as alarm outlier if identified as an alert in three consecutive years	
Minor deviations from SOP	Potential negative alert outliers will not be notified (unless rated as an alarm due to repeat alerts, as specified above)	

Table A2.2: Details of the National Pancreatic Cancer Audit performance indicators used in outlier process

Indicator	Description	Risk Adjustment (Y/N)	Missingness Concern	Rationale for use
90-day survival from diagnosis (adjusted)	Risk-adjusted 90-day survival from date of diagnosis among people with pancreatic cancer (excluding neuroendocrine tumours)	Yes – age, sex, IMD quintile, stage, performance status, receipt of disease-targeted treatment, RCS Charlson scores, year of diagnosis	Missing values for stage, performance status and IMD quintile imputed using multiple imputation	Short-term survival outcomes can reflect how local referral; diagnostic and staging pathways are functioning; risk-adjustment aims to account for differences in casemix
1-year survival from diagnosis (adjusted)	Risk-adjusted 1-year survival from date of diagnosis among people with pancreatic cancer (excluding neuroendocrine tumours)	Yes - age, sex, IMD quintile, stage, performance status, receipt of disease-targeted treatment, RCS Charlson scores, year of diagnosis	Missing values for stage, performance status and IMD quintile imputed using multiple imputation	Longer-term survival outcomes can reflect appropriateness of treatment decisions and follow-up; risk-adjustment aims to account for differences in casemix

3. National Non-Hodgkin Lymphoma Audit (NNHLA)

Table A3.1: Details of the National Non-Hodgkin Lymphoma Audit outlier process

Audit Name	National Non-Hodgkin Lymphoma Audit (NNHLA)		
Patient cohort	National Non-Hodgkin Lymphoma Audit (NNHLA) State of the Nation Report 2025		
	Patients diagnosed with non-Hodgkin lymphoma from 1 January 2022 and 31 December 2022 in England and 1 January 2023 and 31 December 2023 in Wales		
Outliers publication	With State of the Nation report 11.09.2025		
Outlier process	Alarms and positive outliers		
Process to determine if repeat alerts should be rated as alarm outlier	Classifies as alarm if identified two years consecutively		
Minor deviations from SOP	NA		

Table A3.2: Details of the NNHLA performance indicators used in outlier process

Indicator	Description	Risk Adjustment (Y/N)	Missingness Concern	Rationale for use
Overall 1-year survival of people with high-grade lymphoma (BL, DLBCL, mantle cell or high-grade T-cell).	1-year survival for all NHL patients and by grade of lymphoma.	Yes. Indicator adjusted for age, sex, NHL subtype, staging, performance status, Charlson comorbidities index, diagnosis route and diagnosis year.	Multiple imputation with chained equations applied for missing data.	This is reflection of the quality of care of all the multi-disciplinary teams involved. Additionally, variation between providers has been identified.
Overall 2-year survival of people with high-grade lymphoma (BL, DLBCL, mantle cell or high-grade T-cell).	2-year survival for all NHL patients and by grade of lymphoma.	Yes. Indicator adjusted for age, sex, NHL subtype, staging, performance status, Charlson comorbidities index, diagnosis route and diagnosis year.	Multiple imputation with chained equations applied for missing data.	This is reflection of the quality of care of all the multi-disciplinary teams involved. Additionally, variation between providers has been identified.

4. National Ovarian Cancer Audit (NOCA)

Table A4.1: Details of the National Ovarian Cancer Audit outlier process

Audit Name	National Ovarian Cancer Audit (NOCA)		
Patient cohort	All women diagnosed with ovarian cancer (excluding borderline tumours) in NHS trusts in England and Health Boards in Wales in one calendar year.		
Outliers publication	With State of the Nation report 11.09.2025		
Outlier process	As per NATCAN policy for negative and positive alarm 'outliers' in comparison with the overall England and Wales average and subject to minor deviations below.		
Process to determine if repeat alerts should be rated as alarm outlier.	None. To be reviewed for the State of the Nation report 2026 once data are available for two published and one 'in progress' reports.		
Minor deviations from SOP	Outlier reporting is at the level of the Gynaecological Cancer System, not the NHS Trust (England) or Health Board (Wales). Primary correspondence will be with the clinical lead for a system's cancer centre or equivalent and copied to other providers in the system. Patient identifier data are returned to the relevant individual providers.		

Table A4.2: Details of the National Ovarian Cancer Audit performance indicators used in outlier process

Indicator	Description	Risk Adjustment (Y/N)	Missingness Concern	Rationale for use
One-year survival	One-year survival reported for the Gynaecological Cancer System	Y	Missing data for risk adjustment variables are imputed by chained equations.	This outcome indicator, with risk adjustment, reflects the overall quality of care provided in a Gynaecological Cancer System.

5. National Primary Breast Cancer Audit (NAoPri)

Table A5.1: Details of the National Primary Breast Cancer Audit outlier process

Audit Name	National Primary Breast Cancer Audit (NAoPri)
Patient cohort	Patients diagnosed with invasive breast cancer from 1 January 2022 to 31 December 2022 in England and Wales, included in NAoPri report
Outliers publication	Within State of the Nation report 11.09.2025
Outlier process	Alarms and positive outliers
Process to determine if repeat alerts should be rated as alarm outlier.	N/A
Minor deviations from SOP	N/A

Table A5.2: Details of the National Primary Cancer Audit performance indicators used in outlier process

Indicator	Description	Risk Adjustment (Y/N)	Missingness Concern	Rationale for use
3-year survival	3-year, breast cancer specific survival for patients with invasive disease diagnosed in 2022	Y	N	3-year survival selected to allow for sufficient number of events. Survival selected because it provides a measure of quality of care.

6. National Bowel Cancer Audit (NBOCA)

Table A6.1: Details of the National Bowel Cancer Audit outlier process

Audit Name	National Bowel Cancer Audit (NBOCA)		
Patient cohort	National Bowel Cancer Audit (NBOCA) State of the Nation Report October 2025 – individual cohorts described in "Description" column of Table A2 (same for England and Wales)		
Outliers publication	With State of the Nation report 09.10.2025		
Outlier process	Alarm		
Process to determine if repeat alerts should be rated as alarm outlier.	Classified as alarm outlier if identified as an alert in two consecutive years for indicators that are based on 1 year of data		
Minor deviations from SOP	Alerts outliers follow the same process as alarm outliers.		

Table A6.2: Details of the National Bowel Cancer Audit performance indicators used in outlier process

Indicator	Description	Risk	Missingness	Rationale for use
		Adjustment	Concern	
		(Y/N)		
Adjusted 90-day	Proportion of	Υ	5 English NHS	ACPGBI: Guidelines
mortality after	people with bowel		Trusts did not	for the Management
major resection	cancer who die		have sufficient	of Cancer of the
	within 90-days of		completeness of	Colon, Rectum and
	major resection		risk adjustment	Anus (2017) – Surgical
	between January		variables to	Management
	and December		produce a risk-	"Colorectal units
	2023		adjusted	should expect to
			outcome	achieve an operative
				mortality of less than
				20% for emergency
				surgery and less than
				5% for elective
				surgery for colorectal
				cancer."
				QI aim: Improving
				perioperative care.

Indicator	Description	Risk	Missingness	Rationale for use
		Adjustment (Y/N)	Concern	
Adjusted 30-day unplanned return to theatre after major resection	Proportion of people with bowel cancer who have an unplanned return to theatre within 30-days of their major resection between January and December 2023	Y	5 English NHS Trusts did not have sufficient completeness of risk adjustment variables to produce a risk- adjusted outcome	ACPGBI: Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) – Surgical Management "Colorectal units should audit their leak rate for colorectal cancer surgery." QI aim: Improving perioperative care.
Adjusted 30-day unplanned readmission after major resection	Proportion of people with bowel cancer who have an emergency admission for any cause within 30-days of their major resection between January and December 2023	Y	5 English NHS Trusts did not have sufficient completeness of risk adjustment variables to produce a risk- adjusted outcome	Unplanned readmissions are regarded as a quality metric for surgical care. QI aim: Improving perioperative care.
Adjusted 18- month unclosed ileostomy after anterior resection	Proportion of people with rectal cancer who have an unclosed ileostomy 18-months after their anterior resection between April 2018 and March 2023	Y	5 English NHS Trusts did not have sufficient completeness of risk adjustment variables to produce a risk- adjusted outcome	ACPGBI: Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) – Surgical Management "After low anterior resection, a temporary defunctioning stoma should be considered." "The permanent stoma rate following rectal cancer resection of colorectal units should be audited." QI aim: Improving perioperative care.

Indicator	Description	Risk Adjustment (Y/N)	Missingness Concern	Rationale for use
Severe acute toxicity after adjuvant chemotherapy for colon cancer	Proportion of people receiving adjuvant chemotherapy for stage III colon cancer with severe acute toxicity after surgery between 1 Apr 2021 and 31 Oct 2023	Y	2 English NHS Trusts did not have sufficient completeness of risk adjustment variables to produce a risk- adjusted outcome	Boyle JM, et al. Measuring variation in the quality of systemic anti-cancer therapy delivery across hospitals: A national population- based evaluation. Eur J Cancer. 2023 Jan;178:191-204. The delivery of adjuvant chemotherapy is a complex process which includes appropriate patient selection and optimisation, tailoring treatment doses, and the monitoring and management of toxicities. NBOCA have developed and evaluated the use of a national performance indicator to assess hospital variation in severe acute toxicity rates in order to stimulate and support quality improvement. QI aim: Improving oncological care.

Indicator	Description	Risk Adjustment (Y/N)	Missingness Concern	Rationale for use
Adjusted 2-year survival rate after major resection.	2-year survival rate after major resection between April 2021 and March 2022	Y	6 English NHS Trusts did not have sufficient completeness of risk adjustment variables to produce a risk- adjusted outcome	Shulman LN, et al. Survival As a Quality Metric of Cancer Care: Use of the National Cancer Data Base to Assess Hospital Performance. J Oncol Pract. 2018 Jan;14(1):e59-e72. "2-year all-cause mortality rate after major resection is an important quality metric of cancer care." QI aim: Improving oncological care.

7. National Oesophago-Gastric Cancer Audit (NOGCA)

Table A7.1: Details of the National Oesophago-Gastric Cancer Audit outlier process

Audit Name	National Oesophago-Gastric Cancer Audit (NOGCA)			
Patient cohort	National Oesophago-Gastric Cancer Audit (NOGCA) State of the Nation Report September 2025			
T ditellit control	People diagnosed with OG cancer from 1 January 2021 to 31 December 2023 (3-year surgical cohort), England and Wales			
Outliers publication	With State of the Nation report 11.09.2025			
Outlier process	Alarm			
Process to determine if repeat alerts should be rated as alarm outlier.	Classified as alarm outlier if identified as an alert in three consecutive years			
Minor deviations from SOP	N/A			

Table A7.2: Details of the National Oesophago-Gastric Cancer Audit performance indicators used in outlier process

Indicator	Description	Risk	Missingness	Rationale for
		Adjustment	Concern	use
		(Y/N)		
90-day survival	Risk-adjusted	Y - age, sex, IMD	Missing values for	Short-term
after surgery with	proportion of	quintile, stage,	stage,	postoperative
curative intent	people with OG	performance	performance	survival can
(adjusted)	cancer who survive	status, tumour	status and IMD	reflect quality
	at least 90-days	site (C15 or	quintile imputed	of surgical
	after surgery	C16), RCS	using multiple	and
		Charlson	imputation	postoperative
		Comorbidity		care
		Index, year of		
		diagnosis		

8. National Prostate Cancer Audit (NPCA)

Table A8.1: Details of the National Prostate Cancer Audit outlier process

Audit Name	National Prostate Cancer Audit (NPCA)				
	National Prostate Cancer Audit (NPCA) State of the Nation Report 2025				
Patient cohort	Patients who received radical treatment between 1 September 2021 and 31 August 2022 in England and Wales and patients with metastatic disease who received SACT between 1 January and 31 December 2022 in England and 1 April and 31 December 2023 in Wales				
Outliers publication	With State of the Nation report 09.10.2025				
Outlier process	Alarms, Alerts and positive outliers				
Process to determine if repeat alerts should be rated as alarm outlier.	N/A				
Minor deviations from SOP	N/A				

Table A8.2: Details of the National Prostate Cancer Audit performance indicators used in outlier process

Indicator	Description	Risk Adjustment (Y/N)	Missingness Concern	Rationale for use
Proportion of men under 75 years old with newly diagnosed hormone-sensitive metastatic disease receiving systemic treatment intensification	Proportion of people with metastatic prostate cancer under 75 years old who receive initial systemic anti-cancer therapy within 12 months of diagnosis	Yes - age, co-morbidity (Charlson score), frailty and performance status	Patients with missing values for risk adjustment variables were allocated to a missing category for the respective variables	Measure of care received
Proportion of men 75 years and older with newly diagnosed hormone-sensitive metastatic disease receiving systemic treatment intensification	Proportion of people with metastatic prostate cancer 75 years and older who receive initial systemic anti-cancer therapy within 12 months of diagnosis	Yes - age, co-morbidity (Charlson score), frailty and performance status	Patients with missing values for risk adjustment variables were allocated to a missing category for the respective variables	Measure of care received
Proportion of patients experiencing at least one GU complication requiring a procedural/surgical intervention within 2 years of radical prostatectomy	Proportion of patients experiencing at least one GU complication requiring a procedural/surgical intervention within 2 years of radical prostatectomy	Yes – age, risk score, co-morbidity (Charlson score) and deprivation (IMD quintile)	Patients with missing values for risk adjustment variables were allocated to a missing category for the respective variables	Measure of care received
Proportion of patients receiving a procedure of the large bowel and a diagnosis indicating radiation toxicity (GI complication) within 2 years of radical prostate radiotherapy	Proportion of patients receiving a procedure of the large bowel and a diagnosis indicating radiation toxicity (GI complication) within 2 years of radical prostate radiotherapy	Yes – age, risk score, co-morbidity (Charlson score) and deprivation (IMD quintile)	Patients with missing values for risk adjustment variables were allocated to a missing category for the respective variables	Measure of care received